AFLIBERCEPT IN COMBINATION WITH FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: COST-EFFECTIVENESS BASED ON VELOUR BEST EFFICACY SUBGROUP POST-HOC ANALYSIS

被引：4
|
作者：
Echave, M. [1 ]
Oyaguez, I [1 ]
Lamas, M. J. [2 ]
Rubio, M. [3 ]
Subira, R. [3 ]
机构：
[1] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[2] Complexo Hosp Santiago de Compostela, Santiago De Compostela, Spain
[3] Sanofi, Barcelona, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1153
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A454 / A454
页数：1
相关论文
共 50 条
  • [1] AFLIBERCEPT/FOLFIRI (AF) VS PLACEBO/FOLFIRI (PF) IN METASTATIC COLORECTAL CANCER (MCRC): POST-HOC ANALYSIS OF SURVIVAL EXCLUDING ADJUVANT (ADJ)-ONLY PATIENTS IN THE VELOUR TRIAL
    Joulain, F.
    Iqbal, U.
    Diamand, F.
    Van Cutsem, E.
    Tabernero, J.
    Allegra, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 214 - 214
  • [2] A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
    Ian Chau
    Florence Joulain
    Sheikh Usman Iqbal
    John Bridgewater
    BMC Cancer, 14
  • [3] A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
    Chau, Ian
    Joulain, Florence
    Iqbal, Sheikh Usman
    Bridgewater, John
    BMC CANCER, 2014, 14
  • [4] AFLIBERCEPT/FOLFIRI VS PLACEBO/FOLFIRI IN METASTATIC COLORECTAL CANCER: A POST-HOC ANALYSIS OF MEDIAN OVERALL SURVIVAL IN VELOUR FROM THE RETROSPECTIVELY ASSESSED TIME OF STARTING FIRST-LINE TREATMENT
    Josep, Tabernero
    Teresa, Macarulla
    Yves, Humblet
    Albert, ten Tije
    Hendrik, Kroening
    Cristina, Gravalos
    Solenn, Le-Guennec
    Emmanuelle, Dochy
    Eric, Van Cutsem
    ANNALS OF ONCOLOGY, 2014, 25 : 104 - 104
  • [5] Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
    Ge, Pu
    Wan, Ning
    Han, Xiao
    Wang, Xinpei
    Zhang, Jinzi
    Long, Xiaoyi
    Wang, Xiaonan
    Bian, Ying
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE
    Gyldmark, M.
    Aultman, R.
    Siebert, U.
    Sabate, E.
    VALUE IN HEALTH, 2009, 12 (03) : A49 - A49
  • [7] WHO BENEFITS MOST FROM COLLABORATIVE DEMENTIA CARE? A POST-HOC SUBGROUP COST-EFFECTIVENESS ANALYSIS
    Raedke, A.
    Hoffmann, W.
    Michalowsky, B.
    VALUE IN HEALTH, 2019, 22 : S412 - S412
  • [8] AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH FOLFIRI IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER: MEAN OVERALL SURVIVAL FOR SUBGROUPS FROM VELOUR
    Joulain, Florence
    Iqbal, Sheikh
    Diamand, Francoise
    Van Cutsem, Eric
    Hoyle, Martin
    Allegra, Carmen
    ANNALS OF ONCOLOGY, 2012, 23 : 26 - 26
  • [9] Post hoc safety and effectiveness analysis of aflibercept plus FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE
    Cartwright, Thomas H.
    Fakih, Marwan
    Garcia-Alfonso, Pilar
    Linke, Zdenek
    Ruiz Casado, Ana
    Polo Marques, Eduardo
    Picard, Pascaline
    Celanovic, Marina
    Singh, Arvind Rup
    Salinardi, Taylor
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
    Watanabe, Jun
    Terazawa, Tetsuji
    Yamane, Shiho
    Kazama, Hirotaka
    Uetake, Hiroyuki
    Yoshino, Takayuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 130 - 138
12345